A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara) to investigate the value of adding RAD001 to letrozole as a first-line therapy in postmenopausal women with advanced breast cancer

Trial Profile

A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara) to investigate the value of adding RAD001 to letrozole as a first-line therapy in postmenopausal women with advanced breast cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs Everolimus (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top